Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Background The sympathetic nervous system (SNS) regulates glucose metabolism in various organs including the kidneys. The sodium glucose cotransporter 2 (SGLT2) mediates glucose reabsorption in renal proximal tubules and its inhibition has been shown to improve glucose control, cardiovascular and renal outcomes. We hypothesized that SNS-induced alterations of glucose metabolism may be mediated via regulation of SGLT2. Method We used human renal proximal tubule cells to investigate the effects of noradrenaline on SGLT2 regulation. Mice fed a high-fat diet were oral gavaged with dapagliflozin and the expression of noradrenaline and tyrosine hydroxylase was measured in the kidney and heart. Results Noradrenaline treatment resulted in a pronounced increase in SGLT2 and interleukin (IL)-6 expression in HK2 cells and promoted translocation of SGLT2 to the cell surface. In vivo, dapagliflozin treatment resulted in marked glucosuria in high-fat diet-fed mice. SGLT2 inhibition significantly reduced high-fat diet-induced elevations of tyrosine hydroxylase and noradrenaline in the kidney and heart. We also aimed to assess the levels of hypertension-related cytokines in the kidneys of our mice treated with and without dapagliflozin. Excitingly, we demonstrate that SGLT2 inhibition with dapagliflozin promoted a trend towards reduced tumour necrosis factor-alpha and elevated IL-1β protein levels in the kidney. Conclusion Our in-vitro and in-vivo studies provide first evidence for an import…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and therefore this effect may attribute to the inhibition of sympathetic nervous system by SGLT-2i.21,22”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [21]
In the citing paper
“in agreement with studies that SGLT-2i reduces BP but does not elevate or slow down the HR”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [21]
In the citing paper
“In human kidney cells, the neurotransmitter noradrenaline increased SGLT2 expression and promoted SGLT2 translocation to the cell membrane.”
From A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors (2021) · cites this paper as Matthews et al., 2017
In the citing paper
“Further studies in obese mice revealed that SGLT2 inhibition with dapagliflozin leads to significant reductions of intrarenal tyrosine hydroxylase, a marker of sympathetic nerve innervation, and norepinephrine (Matthews et al., 2017).”
From A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors (2021) · cites this paper as Matthews et al., 2017
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60460-8 · Cited by 11,952
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 1×
“Hyperglycaemia is a key characteristic of type 2 diabetes and is associated with the development of microvascular and macrovascular complications as well as diabetes-related mortality [4].”
BackgroundEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · cited 5×
“In addition, we have now uncovered mechanistic insights as to how SGLT2 inhibitors may be exerting their beneficial renal and cardiovascular effects [21,22] by acting on the SNS.”
BackgroundMethodResultInfluentialGrundy, S. M. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.151092 · Cited by 1,563 · cited 1×
“G lobally, it is estimated that greater than 35% of the population are overweight or obese [1] and approximately 30% have the metabolic syndrome [2].”
BackgroundBody Mass Index, Metabolic Syndrome, and Risk of Type 2 Diabetes or Cardiovascular Disease
Meigs, J. B., Wilson, P. W. F., Fox, C. S., Vasan, R. S., Nathan, D. M., Sullivan, L. M., & D’Agostino, R. B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0594 · Cited by 1,062 · cited 1×
“These conditions are associated with an elevated risk for cardiovascular disease as well as the development of type 2 diabetes [3].”
BackgroundRahmoune, H., Thompson, P. W., Ward, J. M., Smith, C. D., Hong, G., & Brown, J. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3427 · Cited by 777
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670 · cited 1×
“SGLT2 was detected using both rabbit anti-SGLT2 polyclonal (Novus Biologicals) and mouse anti-SGLT2 monoclonal (Santa Cruz Biotechnology) in accordance with previous studies [28].”
MethodMahfoud, F., Schlaich, M., Kindermann, I., Ukena, C., Cremers, B., Brandt, M. C., Hoppe, U. C., Vonend, O., Rump, L. C., Sobotka, P. A., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.991869 · Cited by 573 · cited 1×
“Furthermore, therapeutic sympathetic inhibition, either pharmacologically or through interventions such as renal denervation [12], may exert its beneficial effects on glucose metabolism via relative reduction of SGLT-2 expression.”
BackgroundSelf-citationSGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
Vallon, V., Platt, K. A., Cunard, R., Schroth, J., Whaley, J., Thomson, S. C., Koepsell, H., & Rieg, T. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010030246 · Cited by 563 · cited 1×
“The sodium/glucose cotransporters (SGLTs) are the membrane transport proteins that mediate the glucose reabsorption from the lumen of the renal proximal tubules [16].”
Background
Cited by
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Lopaschuk, G. D., & Verma, S. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.004 · Cited by 894
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.031 · Cited by 566
Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects
Griffin, M., Rao, V. S., Ivey-Miranda, J., Fleming, J., Mahoney, D., Maulion, C., Suda, N., Siwakoti, K., Ahmad, T., Jacoby, D., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045691 · Cited by 414
Adiponectin, Leptin and Cardiovascular Disorders
Zhao, S., Kusminski, C. M., & Scherer, P. E. (2021) · Circulation Research · doi:10.1161/circresaha.120.314458 · Cited by 373
Spallone, V. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0259 · Cited by 295
Metadata
- Authors
- Matthews, V. B., Elliot, R. H., Rudnicka, C., Hricova, J., Herat, L., & Schlaich, M. P.
- Affiliations
- The University of Western Australia (AU)
- Corresponding author
- Schlaich, Markus P.
- Venue
- Journal of Hypertension
- Published
- 2017-10
- Volume
- 35
- Issue
- 10
- Pages
- 2059-2068
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W2624457286
- Cited by
- 222
- References
- 39
- Citations by year
- 2026: 9 · 2025: 27 · 2024: 26 · 2023: 21 · 2022: 33 · 2021: 40 · 2020: 37 · 2019: 11 · 2018: 15 · 2017: 3
- FWCI
- 14.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hypertension (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- sympathetic nervous system, SGLT2, SGLT2 inhibition, dapagliflozin, norepinephrine, tyrosine hydroxylase, proximal tubule, glucose reabsorption, glycosuria, interleukin-6, TNF-α, IL-1β, high-fat diet, hypertension, renal inflammation, cardioprotection
- MeSH terms
- Animals, Cells, Cultured, Humans, Kidney Tubules, Proximal, Sympathetic Nervous System, Sodium-Glucose Transporter 2, Mice, Diet, High-Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. https://app.cochat.ai/papers/10.1097/hjh.0000000000001434
- The paper
- Matthews, V. B., Elliot, R. H., Rudnicka, C., Hricova, J., Herat, L., & Schlaich, M. P. (2017). Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. Journal of Hypertension. https://doi.org/10.1097/hjh.0000000000001434
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.